Header

UZH-Logo

Maintenance Infos

Browse by Creators

Navigate back| Up a level
Export as
Number of items: 5.

Studt, J D; Alberio, L; Angelillo-Scherrer, A; Asmis, L M; Fontana, P; Korte, W; Mendez, A; Schmid, P; Stricker, H; Tsakiris, D A; Wuillemin, W A; Nagler, Michael (2017). Accuracy and consistency of anti-Xa activity measurement for determination of rivaroxaban plasma levels. Journal of Thrombosis and Haemostasis, 15(8):1576-1583.

Steiner, U C; Keller, M; Schmid, P; Cichon, S; Wuillemin, W A (2017). Mutational spectrum of the SERPING1 gene in Swiss patients with hereditary angioedema. Clinical and Experimental Immunology, 188(3):430-436.

Marschall, K; Hoernes, M; Bitzenhofer-Grüber, M; Jandus, P; Duppenthaler, A; Wuillemin, W A; Rischewski, J; Boyman, O; Heininger, U; Hauser, T; Steiner, U; Posfay-Barbe, K; Seebach, J; Recher, M; Hess, C; Helbling, A; Reichenbach, J (2015). The Swiss National Registry for Primary Immunodeficiencies: report on the first 6 years' activity from 2008 to 2014. Clinical and Experimental Immunology, 182(1):45-50.

Nendaz, M; Spirk, D; Kucher, N; Aujesky, D; Hayoz, D; Beer, J H; Husmann, M; Frauchiger, B; Korte, W; Wuillemin, W A; Jäger, K; Righini, M; Bounameaux, H (2013). Multicentre validation of the Geneva Risk Score for hospitalised medical patients at risk of venous thromboembolism. Explicit ASsessment of Thromboembolic RIsk and Prophylaxis for Medical PATients in SwitzErland (ESTIMATE). Thrombosis and haemostasis, 111(3):online-.

Asmis, L M; Alberio, L; Angelillo-Scherrer, A; Korte, W; Mendez, A; Reber, G; Seifert, Burkhardt; Stricker, H; Tsakiris, D A; Wuillemin, W A (2012). Rivaroxaban: Quantification by anti-FXa assay and influence on coagulation tests A study in 9 Swiss laboratories. Thrombosis Research, 129(4):492-498.

This list was generated on Fri Apr 26 09:54:27 2019 CEST.